Skip to main content

Advertisement

SpringerLink
Log in

2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

  • Research
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

This retrospective study investigated the prognostic role of disease dissemination features (Dmax and Dmaxbsa) measured by 2-[18F]FDG PET/CT in newly diagnosed Burkitt Lymphoma (BL) patients, comparing their performance with other metabolic parameters. We included 78 patients diagnosed with BL between 2010 and 2022 with an available baseline PET, interim PET/CT (iPET) and end of treatment PET/CT (eotPET) and with a minimum of two 2-[18F]FDG avid lesions present at the baseline scan. Dmax was calculated from the three-dimensional coordinates of the baseline metabolic tumor volume (MTV) by using LIFEx software; Dmaxbsa was calculated as Dmax normalized for body surface area according to the Du Bois method. We evaluated their effect on metabolic treatment response evaluated by PET, on progression free survival (PFS) and on overall survival (OS). Dmaxbsa was significantly associated with tumor stage, bulky and extranodal disease, MTV and TLG. At a median follow-up of 49 months, the median PFS and OS were 45 and 48 months. Dmax and Dmaxbsa were significantly higher in not complete metabolic response than complete metabolic response group at iPET and eotPET.As far as PFS, parameters including iPET/CT, eotPET/CT outcomes, MTV and TLG showed to be independent prognostic factors while Dmax and Dmaxbsa were not significantly associated with the outcome. Dissemination features, together with eotPET/CT results, MTV and TLG, demonstrated to be significantly correlated with OS. In conclusion, in this study we demonstrated that dissemination features derived by 2[18F]-FDG PET/CT were significantly correlated with response to treatment and long-term outcome, independently from other PET features.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

No datasets were generated or analysed during the current study.

References

  1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459

    Article  PubMed  Google Scholar 

  2. Roschewski M, Staudt LM, Wilson WH (2022) Burkitt’s lymphoma. N Engl J Med 387(12):1111–1122. https://doi.org/10.1056/NEJMra2025746

    Article  PubMed  Google Scholar 

  3. Schmitz R, Young RM, Ceribelli M et al (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490(7418):116–120. https://doi.org/10.1038/nature11378

    Article  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  4. Grande BM, Gerhard DS, Jiang A et al (2019) Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 133(12):1313–1324. https://doi.org/10.1182/blood-2018-09-871418

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Crombie J, LaCasce A (2021) The treatment of Burkitt lymphoma in adults. Blood 137(6):743–750. https://doi.org/10.1182/blood.2019004099

    Article  PubMed  CAS  Google Scholar 

  6. López C, Burkhardt B, Chan JKC et al (2022) Nat Rev Dis Primers 8(1):78. https://doi.org/10.1038/s41572-022-00404-3

    Article  PubMed  Google Scholar 

  7. Albano D, Bertagna F, Giubbini (2020) R.18F-FDG PET/CT role in Burkitt lymphoma. Clin Transl Imaging 8:39–45

    Article  Google Scholar 

  8. Just PA, Fieschi C, Baillet G et al (2008) 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS 22:695–700

    Article  PubMed  Google Scholar 

  9. Zeng W, Lechowicz MJ, Winton E et al (2009) Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med 4:355–358

    Article  Google Scholar 

  10. Karantanis D, Durski JM, Lowe VJ et al (2012) 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 75:e68–73

    Article  Google Scholar 

  11. Carrillo-Cruz E, Rodrıguez MS, Borrego-Dorado I et al (2015) Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma. Eur J Haematol 94:23–30

    Article  PubMed  CAS  Google Scholar 

  12. Albano D, Bosio G, Re A et al (2018) Metabolic behaviour and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt lymphoma: role of Deauville and IHP criteria. Leuk Lymphoma 3:1–8

    Google Scholar 

  13. Wei WX, Huang JJ, Li WY et al (2015) Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma. Chin J Cancer 2(34):608–613

    Google Scholar 

  14. Albano D, Bosio G, Pagani C et al (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging 46:87–96

    Article  PubMed  Google Scholar 

  15. Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, Meignan M, Buvat I (2020) 18F-FDG PET dissemination features in diffuse large B-Cell lymphoma are Predictive of Outcome. J Nucl Med 61(1):40–45. https://doi.org/10.2967/jnumed.119.229450

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Albano D, Treglia G, Dondi F, Calabrò A, Rizzo A, Annunziata S, Guerra L, Morbelli S, Tucci A, Bertagna F (2023) 18F-FDG PET/CT maximum tumor dissemination (Dmax) in lymphoma: a New Prognostic factor? Cancers (Basel). 15(9):2494. https://doi.org/10.3390/cancers15092494

  17. Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Spiekermann K et al (2014) Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124:3870–3879

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Ferreri AJ, Bruno VM, Donadoni G, Cattaneo C, Fumagalli L, Foppoli M et al (2012) Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. Br J Haematol 159:252–255

    Article  PubMed  CAS  Google Scholar 

  19. Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imag 42(2):328–354. https://doi.org/10.1007/s00259-014-2961-x

    Article  CAS  Google Scholar 

  20. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol 32(27):3059–3067. https://doi.org/10.1200/jco.2013.54.8800

    Article  PubMed  PubMed Central  Google Scholar 

  21. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. ;32:3048–58

  22. Nioche C, Orlhac F, Boughdad S et al (2018) LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 78(16):4786–4789. https://doi.org/10.1158/0008-5472.CAN-18-0125

    Article  PubMed  CAS  Google Scholar 

  23. Dubois D, Dubois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863–871

    Article  CAS  Google Scholar 

  24. Frood R, Burton C, Tsoumpas C, Frangi AF, Gleeson F, Patel C, Scarsbrook A (2021) Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. Eur J Nucl Med Mol Imaging 48(10):3198–3220. https://doi.org/10.1007/s00259-021-05233-2

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli ME, Ciavarella S, Vegliante MC, Nioche C, Meignan M, Merli F, Versari A, Ciarrocchi A, Buvat I, Luminari S (2022) Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: a radio-genomic study. Hematol Oncol 40(4):645–657. https://doi.org/10.1002/hon.3025

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I (2021) Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. Ann Oncol 32(3):404–411. https://doi.org/10.1016/j.annonc.2020.11.019

    Article  PubMed  Google Scholar 

  27. Bailly C, Eugène T, Couec ML, StrulluM, Frampas E, Campion L et al (2014) Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne) 16(1):54

    Google Scholar 

  28. Wen WX, Huang JJ, Li WY, Zhang X, Xia Y, Jiang WQ et al (2015) Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma. Chin J Cancer 2(34):608–613

    Google Scholar 

  29. Zeng W, Lechowicz MJ, Winton E, Cho SM, Galt JR, Halkar R (2009) Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med 4:355–358

    Article  Google Scholar 

  30. Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E et al (2012) 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 75:e68–73

    Article  Google Scholar 

Download references

Funding

No funding.

Author information

Authors and Affiliations

  1. Nuclear Medicine, ASST Spedali Civili Brescia, Brescia, 25123, Italy

    Domenico Albano, Anna Calabrò, Anna Talin, Francesco Dondi & Francesco Bertagna

  2. Nuclear Medicine, University of Brescia, Brescia, Italy

    Domenico Albano, Anna Calabrò, Anna Talin, Francesco Dondi & Francesco Bertagna

  3. Division of Hematology, ASST Spedali Civili Brescia, Brescia, Italy

    Chiara Pagani & Alessandra Tucci

  4. Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland

    Giorgio Treglia

  5. Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

    Giorgio Treglia

  6. Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland

    Giorgio Treglia

Authors
  1. Domenico Albano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Calabrò
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Talin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Dondi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chiara Pagani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alessandra Tucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giorgio Treglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francesco Bertagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, D.A. and A.C.; methodology, G.T. and F.D.; data curation, A.T.; A.C.; C.P. and F.D.; supervision,A.T. and F.B.; writing—original draft preparation, D.A., G.T. and A,C. Preparation figures: C.P., A.T., F.D. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Domenico Albano.

Ethics declarations

Ethical approval

Ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical review and approval were waived for this study (observational retrospective) due to the retrospective design of the study, according to local laws.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1:

ROC: receiver operating characteristic (ROC); AUC; area under the curve; OS: overall survival; SUV: standardized uptake value; bw: body wheight; lbm:lean body mass; bsa: body surface area; MTV: total metabolic tumor volume; TLG: total lesion glycolysis; Dmax: maximum tumor dissemination

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albano, D., Calabrò, A., Talin, A. et al. 2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome. Ann Hematol (2024). https://doi.org/10.1007/s00277-024-05672-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00277-024-05672-5

Keywords

Search

Navigation